InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

Current share price for OSL : $0.700 0.01 (1.41%)+

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 Application for quotation of securities - OSL 17 Jul 2026 3:31PM $1.460 $0.700 fallen by 52.05%
$26 Investor Presentation 15 Jul 2026 8:57AM $1.375 $0.700 fallen by 49.09%
$26 OSPREY Registry Abstract Accepted for EANM 2026 Congress 14 Jul 2026 8:54AM $1.400 $0.700 fallen by 50%
$26 OncoSil Medical Completes Manufacturing Validation 13 Jul 2026 8:39AM $1.320 $0.700 fallen by 46.97%
$26 TRIPP-FFX Results Presented at ESMO GI 2026 6 Jul 2026 8:49AM $0.985 $0.700 fallen by 28.93%
$26 OncoSil Medical Files for FDA Approval 3 Jul 2026 8:27AM $0.810 $0.700 fallen by 13.58%
$26 OncoSil Selected for Major European Pancreatic Cancer Study 2 Jul 2026 8:46AM $0.755 $0.700 fallen by 7.28%
$26 TRIPP-FFX Abstract Published on ESMO GI 2026 Website 30 Jun 2026 8:47AM $0.675 $0.700 risen by 3.70%
$26 Notice under ASX Listing Rule 3.10A 29 Jun 2026 3:54PM $0.675 $0.700 risen by 3.70%
$26 Publication verifies OncoSil strong localisation in pancreas 12 Jun 2026 9:04AM $0.525 $0.700 risen by 33.33%
$26 OncoSil Medical Launches Investor Hub 12 Jun 2026 8:30AM $0.525 $0.700 risen by 33.33%
$26 Change in substantial shareholding from AEF 11 Jun 2026 10:12AM $0.550 $0.700 risen by 27.27%
$26 TRIPP FFX accepted for oral presentation at ESMO GI 2026 10 Jun 2026 9:04AM $0.575 $0.700 risen by 21.74%
$26 US FDA HDE and TRIPP-FFX Study Presentation 9 Jun 2026 9:48AM $0.435 $0.700 risen by 60.92%
$26 OncoSil progresses HDE with US FDA 9 Jun 2026 9:48AM $0.435 $0.700 risen by 60.92%
$26 TRIPP-FFX Clinical Trial Meets Co-Primary Endpoints 9 Jun 2026 9:47AM $0.435 $0.700 risen by 60.92%
$26 Trading Halt 4 Jun 2026 9:09AM $0.435 $0.700 risen by 60.92%
$26 TRIPP FFX Clinical Trial to Report Results in June 1 Jun 2026 8:59AM $0.510 $0.700 risen by 37.25%
$26 Key New Ethics Approval for Italian Patient Registry 28 May 2026 9:05AM $0.500 $0.700 risen by 40%
$26 Application for quotation of securities - OSL 27 May 2026 3:22PM $0.500 $0.700 risen by 40%
$26 Notification regarding unquoted securities - OSL 27 May 2026 3:20PM $0.500 $0.700 risen by 40%
$26 Appointment of Company Secretary 25 May 2026 3:49PM $0.535 $0.700 risen by 30.84%
$26 New Clinical Evidence for OncoSil Device Presented at ASCO 22 May 2026 9:14AM $0.510 $0.700 risen by 37.25%
$26 OncoSil Medical Receives TGA Approval in Australia 20 May 2026 9:17AM $0.390 $0.700 risen by 79.49%
$26 OSPREY Interim Results Presented at ESGE Days 2026 15 May 2026 8:31AM $0.450 $0.700 risen by 55.56%

26 - 50 of 812 results

Page 2 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.